Urgent.News

What's breaking now, across thousands of outlets.

Business

College sports meltdown fuels push on Capitol Hill

The ongoing public outcry over pro athletes attempting to come back to college sports is boosting the Senate’s bipartisan bill.

College sports meltdown fuels push on Capitol Hill

A public backlash against professional athletes attempting to return to college sports is bolstering support for a Senate bipartisan bill. As the Senate returns in September, the Protect College Sports Act is set to be considered, addressing the ongoing controversy. Tim Buckley, an NCAA spokesman, acknowledged that the recent public outrage has helped shift some minds on Capitol Hill, potentially strengthening the bill's support.

The Big Ten and the Southeastern Conference have taken steps to ban players with pro contracts from participating in college sports, but these measures are vulnerable to legal challenges, which adds uncertainty for athletes and fans alike. Senate Commerce Committee Chairman Ted Cruz and President Donald Trump had initially sought to pass the bill before the August recess, but the bill's complex nature led to a delay until September.

This delay may prove beneficial for the bill, as it could accumulate the necessary 60 votes as the controversy surrounding pro players attempting to return to college sports intensifies. According to Buckley, public opinion is clear: allowing college sports as a fallback for pro athletes is widely unpopular.

Written by urgent.news from Semafor's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at semafor.com →

More in Business

Turkey probes Israeli pharmaceutical company Teva over claims it blocked rivals in drug market

The Turkish investigation was opened against Teva International, its subsidiary Teva Europe, and its subsidiary in Turkey to determine whether the law was violated.

  • Turkish Competition Authority investigates Teva for alleged market manipulation.
  • Teva's actions in generic drug sector include patent misuse and misleading health info.
  • Investigation launched against Teva International, Teva Europe, and Teva Turkey subsidiary.

More from Thursday 27 August →